Asociación Madrileña de Hematología y Hemoterapia

Ensayos Clínicos Activos
de Hematología y Hemoterapia en la Comunidad de Madrid

Borrar filtro

Listado de Ensayos Clínicos ordenados por  
Recientes

Se han encontrado 813 ensayos

A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies Reclutando

Fase
Fase II
Patología
Leucemia linfática crónica y otros SLPC, Trombosis y Anticoagulantes, Leucemia mieloide crónica, Linfoma, Leucemia
Centros investigadores
H. Fundación Jiménez Díaz
MD Anderson Cancer Center Madrid
Descripción
Cohort 1 and Cohort 2: Assess the anticancer activity of emavusertib in combination with zanubrutinib

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Reclutando

Fase
Fase III
Patología
Leucemia linfática crónica y otros SLPC, Leucemia mieloide aguda, Leucemia mieloide crónica, Linfoma, Leucemia
Centro investigador
H. Fundación Jiménez Díaz
Descripción
To evaluate the efficacy of BGB-16673 compared to pirtobrutinib as measured by progression-free survival (PFS) determined by independent review committee (IRC)

A randomized phase III, global, multicentre, open label clinical trial comparing Venetoclax Azacitidine and Quizartinib vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy. Reclutando

Fase
Fase III
Patología
Leucemia mieloide aguda, Linfoma, Leucemia
Centros investigadores
H. Fundación Jiménez Díaz
H.U. Infanta Leonor
H.U. Quirónsalud Madrid
H.U. 12 de Octubre
H.U. Ramón y Cajal
H.U. Clínico San Carlos
H.U. Infanta Sofia
H. Principe de Asturias
Descripción
To compare the OS rate between the experimental arm with triple combination of venetoclax, azacitidine and quizartinib vs. standard therapy (venetoclax plus azacitidine)

Single-center phase I/IIa study of infusion of autologous peripheral blood T cells expanded and genetically modified by Sleeping Beauty family transposons to express a chimeric antigen receptor with anti-CD19 specificity conjugated with the 4-1BB costimulatory region and CD3z and huEGFRt signal transmission (TranspoCART19) in patients with CD19+ acute lymphoblastic leukemia resistant or refractory to treatment Reclutando

Fase
Fase I-II
Patología
Leucemia mieloide aguda, Terapia celular y T-CARs, Trasplante de progenitores hematopoyéticos, Linfoma, Leucemia
Descripción
Phase 1: To determine the maximum tolerated dose (MTD) and/or recommended dose of TranspoCART19 cells in patients with treatment-resistant or refractory CD19+ acute lymphoblastic leukemia. Phase 2: ...

A modular Phase I/II, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of AZD4512 monotherapy or in combination with anticancer agent(s) in participants with Acute Lymphoblastic Leukemia Reclutando

Fase
Fase I-II
Patología
Leucemia mieloide aguda, Linfoma, Leucemia
Descripción
Module 1 Dose Escalation: To assess the safety and tolerability of AZD4512 in participants with R/R B-ALL [Ph(-) and Ph(+)] as defined by NCCN guidelines Module 1 Dose Escalation: To identify the MTD ...

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination with Elranatamab in Participants with Relapsed and/or Refractory Multiple Myeloma Reclutando

Fase
Fase I-II
Patología
Mieloma Múltiple y otras gammapatías
Descripción
The main goal is to determine the safety and tolerability of Mezigdomide in combination with Elranatamab in participants with RRMM and to determine the recommended Phase 2 dose (RP2D; the dose to be u...

Esta web utiliza 'cookies' propias y de terceros para ofrecerte una mejor experiencia y servicio. Al navegar o utilizar esta plataforma, aceptas el uso que hacemos de ellas. Puedes cambiar tu propia configuración de 'cookies' en cualquier momento. Si continúas navegando, consideramos que aceptas el uso de cookies.

Aceptar